{"acquisitions":[],"changes":[],"country":"US","description":"Crystalys Therapeutics develops dotinurad, a once-daily oral URAT1 inhibitor that lowers serum uric acid in gout patients by promoting urinary excretion. It treats US gout patients with inadequate response to first-line urate-lowering therapy. Dotinurad has already treated 1.2M+ patients in Japan since 2020 before its US Phase 3.","domain":"crystalys.com","employees":null,"founded":2023,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.787936,"lng":-122.40752,"location":"San Francisco CA","multiples":[],"name":"Crystalys Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":205000000,"connectionsAmong":[],"currency":"USD","date":"2025-10-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"crystalys-com-2025-10-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"crystalys-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"crystalys.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://crystalys.com"},{"fact":"description","publisher":"crystalys.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://crystalys.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":250000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}